


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

Complete if Known

 <p>O P E INFORMATION DISCLOSURE STATEMENT BY APPLICANT DEC 14 2004 (use as many sheets as necessary)</p>	Application Number	10/618,444
	Filing Date	July 11, 2003
	First Named Inventor	Julie K. Andersen
	Group Art Unit	1642
	Examiner Name	Unassigned
	Attorney Docket Number	314-300710US
	Date Submitted	December 8, 2004

## U.S. PATENT DOCUMENTS


Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)			
DK	1	5,206,226		Sabin	4/27/1993	
	2	5,906,996		Murphy	5/25/1999	
	3	6,417,177		Nelson	7/9/2002	
✓	4	6,573,257		Malfroy-Camine et al.	7/3/2003	

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appeal	T
		Office	Number	Kind Code (if known)				

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
DK	5	Adams and Odunze (1991) <i>Free Radic Biol. Med.</i> 10, 161-169	
	6	Andersen, J.K. (2001) Pp. 11-25 In: <i>Ageing Vulnerability: Causes and Interventions</i> , Novartis	
	7	Foundation Symposium 235, John Wiley and Sons, Inc	
	8	Beal (1992) <i>Ann. Neurol.</i> 31: 119-130	
	9	Ben-Shachar et al. (1991) <i>J. Neurochem.</i> , 56(4): 1441-1444	
	10	Berg et al. (2001) <i>J. Neurochem.</i> 79: 225-236	
	11	Bush and Masters (2001) <i>Science</i> 292: 2251-2252	
	12	Castellani et al. (2000) <i>Proc. Natl. Acad. Sci. USA</i> 98: 14669-14674	
	13	Chemy et al. (2001) <i>Neuron</i> 30: 665-676	
	14	Connor et al. (1995) <i>J. Neurochem.</i> 65: 717-724	
	15	Connor et al. (2001) <i>Pediatr. Neurol.</i> 25: 118-129	
✓	16	Cozzi et al. (2000) <i>J. Biol. Chem.</i> 275: 25122-25129	


Examiner Signature		Date Considered	12/12/03
--------------------	---	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/618,444
		Filing Date	July 11, 2003
		First Named Inventor	Julie K. Andersen
		Group Art Unit	1642
		Examiner Name	Unassigned
		Attorney Docket Number	314-300710US
		Date Submitted	December 8, 2004

<input checked="" type="checkbox"/>	17	Curtis <i>et al.</i> (2001) <i>Nat. Genet.</i> 28: 350-354
	18	Dexter <i>et al.</i> (1987) <i>Lancet</i> 21: 1219-1220
	19	Dexter <i>et al.</i> (1989) <i>J. Neurochem.</i> 52: 1830-1836
	20	Du <i>et al.</i> (2001) <i>Proc. Natl. Acad. Sci. USA</i> 98: 14669-14674
	21	Galvani <i>et al.</i> (1995) <i>Toxic In Vitro</i> , 9(4): 365-368
	22	Gassen <i>et al.</i> (1997) <i>Pharmacol., &amp; Toxicol.</i> , 80: 159-166
	23	Gerlach <i>et al.</i> (1994) <i>J. Neurochem.</i> 63:793-807
	24	Griffiths <i>et al.</i> (1999) <i>Brain</i> 122: 667-673
	25	Gutteridge (1992) <i>Ann. Neurol.</i> 32: S16-S21
	26	Han <i>et al.</i> (2000) <i>Cell Mol. Biol.</i> 46: 517-528
	27	Harrison and Arosio (1996) <i>Biochim. Biophys. Acta</i> 1275: 161-203
	28	Huang <i>et al.</i> (1999) <i>J. Biol. Chem.</i> 274: 37111-37116
	29	Kato, <i>et al.</i> (2001) <i>Am. J. Hum. Genet.</i> 69: 191-197
	30	Kaur and Andersen (2002) <i>Aging Cell.</i> 1(1): 17-21
	30	Kaur and Andersen (2004) <i>Ageing Res Rev.</i> 3(3): 327-43
	32	Kaur <i>et al.</i> (2003) <i>Neuron.</i> 37(6): 889-890.
	33	Kidani <i>et al.</i> (1974) <i>Jap. Analyst</i> 23, 1375-1378
	34	Lan and Jiang (1997) <i>J. Neural Transm.</i> 104: 649-660
	35	Marciani <i>et al.</i> (1991) <i>Haematologica</i> 76: 131-134
	36	Orino <i>et al.</i> (2001) <i>Biochem. J.</i> 357: 241-247
	37	Porter and Huehns (1989) <i>Baillieres Clin. Haematol.</i> 2: 459-474
	38	Sofic <i>et al.</i> (1988) <i>J. Neural. Transm.</i> 74: 199-205
	39	Sofic <i>et al.</i> (1991) <i>J. Neurochem.</i> 56: 978-982
<input checked="" type="checkbox"/>	40	Thompson <i>et al.</i> (2001) <i>Brain Res. Bull.</i> 55: 155-164


Examiner Signature		Date Considered	12/12/05
--------------------	---	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/618,444
(use as many sheets as necessary)		Filing Date	July 11, 2003
		First Named Inventor	Julie K. Andersen
		Group Art Unit	1642
		Examiner Name	Unassigned
		Attorney Docket Number	314-300710US
		Date Submitted	December 8, 2004

<i>DK</i>	41	Yantiri and Andersen (1999) <i>IUBMB Life</i> 48: 1-3	
1	42	Yassin, et al. (2000) <i>J. Neurol. Sci.</i> 173: 40-44	
	43	Yoshida et al. (2001) <i>J. Synchrotron Radiat.</i> 8: 998-1000	
<i>V</i>	44	Youdim et al. (1993) <i>Mov. Dis.</i> 8: 1-12	

Examiner Signature		Date Considered	12/12/05
-----------------------	---	--------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



PTO/SB/08A (04-03)

Approved for use through 04/30/2003, OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

~~Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.~~

<p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p><i>(use as many sheets as necessary)</i></p>	<p><b>Complete if Known</b></p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 45%;">Application Number</td> <td>10/618,444</td> </tr> <tr> <td>Filing Date</td> <td>July 11, 2003</td> </tr> <tr> <td>First Named Inventor</td> <td>Julie K. Andersen</td> </tr> <tr> <td>Group Art Unit</td> <td>Unassigned</td> </tr> <tr> <td>Examiner Name</td> <td>Unassigned</td> </tr> <tr> <td>Attorney Docket Number</td> <td>314-300710US</td> </tr> <tr> <td>Date Submitted</td> <td>May 10, 2004</td> </tr> </table>	Application Number	10/618,444	Filing Date	July 11, 2003	First Named Inventor	Julie K. Andersen	Group Art Unit	Unassigned	Examiner Name	Unassigned	Attorney Docket Number	314-300710US	Date Submitted	May 10, 2004
Application Number	10/618,444														
Filing Date	July 11, 2003														
First Named Inventor	Julie K. Andersen														
Group Art Unit	Unassigned														
Examiner Name	Unassigned														
Attorney Docket Number	314-300710US														
Date Submitted	May 10, 2004														

## **U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)			
DK	1	5,980,914		Gerolymatos	11/9/1999	

## **FOREIGN PATENT DOCUMENTS**

#### **OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
DK	2	BEN-SHACHAR ET AL. (1991) "The Iron Chelator Desferrioxamine (Desferal) Retards 6-Hydroxydopamine-Induced Degeneration of Nigrostriatal Dopamine Neurons" Journal of Neurochemistry, Vol. 56, No. 4, pp. 1441-1444	
↓	3	GALVANI ET AL. (1995) "Mitochondrial Toxicity of Iron and the Protective Role of Ferritin on Dopaminergic PC12 Cell Line" Toxic In Vitro Vol.9, No. 4, pp. 365-368	
↓	4	GASSEN ET AL. (1997) "The Potential Role in Iron Chelators in the Treatment of Parkinson's Disease and Related Neurological Disorders" Pharmacology & Toxicity Vol. 80, pp. 159-166	

Examiner Signature		Date Considered	12/12/03
-----------------------	---	--------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.